Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0YF6K
|
|||
| Drug Name |
HER2-specific CAR T cell
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Atypical teratoid/rhabdoid tumour [ICD-11: 2A00.1Y] | Phase 1 | [1] | |
| Choroid plexus carcinoma [ICD-11: 2A02.12] | Phase 1 | [1] | ||
| Ependymoma [ICD-11: 2A00.0Y] | Phase 1 | [1] | ||
| Gastric adenocarcinoma [ICD-11: 2B72] | Phase 1 | [1] | ||
| Germ cell tumour [ICD-11: 2C80.2] | Phase 1 | [1] | ||
| Glioma [ICD-11: 2A00.0; ICD-9: 191] | Phase 1 | [1] | ||
| Medulloblastoma [ICD-11: 2A00.10; ICD-10: C71.6; ICD-9: 191] | Phase 1 | [1] | ||
| Pineoblastoma [ICD-11: 2A00.20] | Phase 1 | [1] | ||
| Company |
Seattle Children's Hospital
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03500991) HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.